Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934200 · ClinicalTrials.gov registry record · Phase 2
Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
A Phase 2 study of Food Hypersensitivity, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06934200 is a Phase 2 study of Food Hypersensitivity that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 32 participants, below the 4,656-participant average among 5 other Food Hypersensitivity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06934200, a Phase 2 study of Food Hypersensitivity, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to. The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.
Conditions Studied
Interventions
- DRUG Omalizumab
Study Locations (1)
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2027-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06934200
The ClinicalTrials.gov registry entry for NCT06934200 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 5 other Food Hypersensitivity trials with a reported enrollment target (99% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Food Hypersensitivity appearing as the primary indexed condition, and to 1 intervention - of which Omalizumab is the first listed.
NCT06934200 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06934200 about?
NCT06934200 is a clinical study titled "Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels". In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to...
What is the current status of trial NCT06934200?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-05-19. Estimated completion is 2027-10-15.
What conditions does trial NCT06934200 study?
This clinical trial studies the following conditions: Food Hypersensitivity.
What interventions are being tested in trial NCT06934200?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT06934200?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06934200 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Milk Allergy and Tolerance in Children
COMPLETED · Phase 2
-
A Study of Sublingual Immunotherapy in Peanut-allergic Children
COMPLETED · Phase 2
-
A Registry for the Food Allergy Community
RECRUITING
-
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
RECRUITING · Phase 1
-
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.